 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Convidecia Air (Ad5-nCoV-IH) / CanSino
Clinical, Journal: Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. (Pubmed Central) - Nov 7, 2023
The seroconversion rates of neutralizing antibodies against BA.1 in Ad5-nCoVO-IH, Ad5-nCoV/O-IH, and Ad5-nCoV-IH groups were 56.00%, 59.60% and 48.67% with no significant difference among the groups. Overall, the investigational vaccines were demonstrated to be safe and well tolerated in adults, and was highly effective in inducing mucosal immunities in addition to humoral and cellular immune responses defending against SARS-CoV-2 variants.Trial registration: Chictr.org identifier: ChiCTR2200063996.
- || Ad5-nCoV-IH / CanSino
Enrollment change, Trial withdrawal: A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (?18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - Jun 18, 2023
P3, N=0, Withdrawn, Sponsor: CanSino Biologics Inc.
Overall, the investigational vaccines were demonstrated to be safe and well tolerated in adults, and was highly effective in inducing mucosal immunities in addition to humoral and cellular immune responses defending against SARS-CoV-2 variants.Trial registration: Chictr.org identifier: ChiCTR2200063996. N=1350 --> 0 | Not yet recruiting --> Withdrawn
- || Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Convidecia Air (Ad5-nCoV-IH) / CanSino
Enrollment change, Trial withdrawal: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) (clinicaltrials.gov) - Jun 18, 2023
P3, N=0, Withdrawn, Sponsor: CanSino Biologics Inc.
N=1350 --> 0 | Not yet recruiting --> Withdrawn N=13000 --> 0 | Not yet recruiting --> Withdrawn
- ||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax
Trial completion, Viral vector: IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - Jun 18, 2023
P3, N=540, Completed, Sponsor: CanSino Biologics Inc.
N=13000 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Ad5-nCoV-IH / CanSino
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (clinicaltrials.gov) - Jun 15, 2023
P3, N=91, Terminated, Sponsor: CanSino Biologics Inc.
Active, not recruiting --> Completed N=1000 --> 91 | Trial completion date: Aug 2023 --> Jan 2023 | Recruiting --> Terminated | Trial primary completion date: May 2023 --> Jan 2023; Difficulty recruiting subjects, so the study was terminated.
- ||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax
Enrollment closed, Viral vector: IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - Jan 3, 2023
P3, N=540, Active, not recruiting, Sponsor: CanSino Biologics Inc.
N=1000 --> 91 | Trial completion date: Aug 2023 --> Jan 2023 | Recruiting --> Terminated | Trial primary completion date: May 2023 --> Jan 2023; Difficulty recruiting subjects, so the study was terminated. Recruiting --> Active, not recruiting
- |||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax
Enrollment open, Viral vector: IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - Nov 1, 2022
P3, N=540, Recruiting, Sponsor: CanSino Biologics Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Ad5-nCoV-IH / CanSino
Trial completion date, Trial initiation date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - Oct 31, 2022
P3, N=1350, Not yet recruiting, Sponsor: CanSino Biologics Inc.
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Jun 2023 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Nov 2022 --> Mar 2023
- |||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Ad5-nCoV-IH / CanSino
Enrollment open, Enrollment change: A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (clinicaltrials.gov) - Sep 7, 2022
P3, N=1000, Recruiting, Sponsor: CanSino Biologics Inc.
Trial completion date: Mar 2023 --> Jun 2023 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Nov 2022 --> Mar 2023 Not yet recruiting --> Recruiting | N=2000 --> 1000
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax
New P3 trial, Viral vector: IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - Aug 26, 2022
P3, N=540, Not yet recruiting, Sponsor: CanSino Biologics Inc.
- |||| Ad5-nCoV-IH / CanSino
Trial completion: Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults (clinicaltrials.gov) - Aug 16, 2022
P4, N=300, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Not yet recruiting --> Recruiting | N=2000 --> 1000 Recruiting --> Completed
- |||||||||| Ad5-nCoV-IH / CanSino
New P3 trial: A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - Jul 5, 2022
P3, N=1350, Not yet recruiting, Sponsor: CanSino Biologics Inc.
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Ad5-nCoV-IH / CanSino
New P3 trial: A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (clinicaltrials.gov) - Dec 23, 2021
P3, N=2000, Not yet recruiting, Sponsor: CanSino Biologics Inc.
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Convidecia Air (Ad5-nCoV-IH) / CanSino
New P3 trial: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) (clinicaltrials.gov) - Nov 18, 2021
P3, N=13000, Not yet recruiting, Sponsor: CanSino Biologics Inc.
- |||| Ad5-nCoV-IH / CanSino
Enrollment open: Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults (clinicaltrials.gov) - Sep 29, 2021
P4, N=300, Recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Ad5-nCoV-IH / CanSino
New P4 trial: Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults (clinicaltrials.gov) - Jul 7, 2021
P4, N=300, Not yet recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention